Monte Rosa Therapeutics Inc
GLUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.02B
Close$
$24.19
103.4% upside
Current Fair Value
103.4% upsideUndervalued by 103.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.02 Billion |
|---|---|
| Enterprise Value | $994.72 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.59 |
| Beta | 1.5 |
| Outstanding Shares | 85,226,427 |
Return
| Return on Equity | -33.06% |
|---|---|
| Return on Assets | -23.15% |
| Return on Invested Capital | -27.96% |
Valuation & Multiples
| P/E Ratio | -5.56 |
|---|---|
| PEG | -2.2 |
| Price to Sales | - |
| Price to Book Ratio | 2.38 |
| Enterprise Value to Revenue | 34.63 |
| Enterprise Value to EBIT | -5.65 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$12.91 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$31.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0978▼ 26.90% |
|---|---|
| Total Calls | 535,934▲ 157.29% |
| Total Puts | 52,400▼ 31.41% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 109.46%▲ 6.34% |
|---|---|
| Total Invested | $2.26B▲ 57.79% |
| Investors Holding | 202▲ 6.00% |
ESG Score
No data
About Monte Rosa Therapeutics Inc
60 employees